Results 121 to 130 of about 21,815 (182)

USP13 promotes enzalutamide resistance by catalyzing depolyubiquitination of PCMT1 in prostate cancer

open access: yesCell Death and Disease
Castrate resistant prostate cancer (CRPC) is often driven by constitutively active androgen receptor and AR splicing variants that become resistant to established hormonal therapy strategies such as enzalutamide.
Zhipeng Wang   +11 more
doaj   +1 more source

Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study

open access: yesBMC Research Notes
Objective Recent preclinical and retrospective clinical evidence shows that androgen receptor (AR)-mediated signals have significant roles in development of non-muscle invasive bladder cancer (NMIBC).
Takashi Kawahara   +5 more
doaj   +1 more source

Practical guide to the use of enzalutamide.

open access: yes, 2014
INTRODUCTION: We summarize the development, definitive trials, and practical use of enzalutamide for practicing urologists and medical oncologists. The care paradigm for patients with metastatic castration resistant prostate cancer (mCRPC) is a changing ...
Hoffman-Censits, Jean, Kelly, Wm Kevin
core  

Metformin in overcoming enzalutamide resistance in castration-resistant prostate cancer

open access: yes
Androgen deprivation is the standard treatment for patients with prostate cancer. However, the disease eventually progresses as castration-resistant prostate cancer (CRPC). Enzalutamide, an androgen receptor inhibitor, is a typical drug for treating CRPC
Liu, Jinpeng   +5 more
core   +1 more source

High Mobility Group AT-hook 2: A Biomarker Associated with Resistance to Enzalutamide in Prostate Cancer Cells

open access: yes
Metastatic prostate cancer (mPCa) is a leading cause of mortality, partly due to its resistance to anti-androgens like enzalutamide. Snail can promote this resistance by increasing full-length AR and AR-V7.
Taaliah Campbell   +4 more
core   +1 more source

Enzalutamide Plus ADT for the Treatment of mHSPC: Real-World Evidence from a Bulgarian Cohort. [PDF]

open access: yesCancers (Basel)
Manova M   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy